Printer Friendly

Galenica Pharmaceuticals' Immune Enhancer GPI-0100 Found To be More Effective in Stimulating an Immune Response.

BIRMINGHAM, Ala. -- Galenica Pharmaceuticals today announced that a scientific communication published in the prestigious Proceedings of the National Academy of Sciences, USA, reported that Galenica's immune enhancer or adjuvant GPI-0100 stimulated higher antibody titers than the adjuvant QS-21. The independent study, published in the October 15 issue and entitled, "On the power of the chemical synthesis: Immunological evaluation of models for multiantigenic carbohydrate-based vaccines," is authored by scientists from the Memorial Sloan-Kettering Cancer Center, Laboratories of Tumor Vaccinology and Bioorganic Chemistry.

The paper addresses the development of novel synthetic multivalent vaccines containing different tumor-associated carbohydrate antigens, and compares the capacity of QS-21 and the related but stable and significantly less toxic GPI-0100 to enhance an antibody response. According to the authors, "The adjuvants, although related, proved significantly different, in that GPI-0100 consistently induced higher titers of antibodies than QS-21." Moreover, the authors report that, "Because GPI-0100 is less toxic than QS-21, greater quantities of GPI-0100 could be safely administered to the mice, and this resulted in a commensurate increase in antibody production."

An immune enhancer or adjuvant is a critical vaccine component that is required to stimulate a protective and/or therapeutically effective immune response against cancer cells or infectious agents. Galenica's lead adjuvant, GPI-0100, is a semi-synthetic derivative from certain natural saponins which have the capability of stimulating Th1 immunity with production of antibodies capable of mediating ADCC and of antigen-specific cytotoxic T cells (CTL) that will seek out and destroy cells carrying abnormal markers such as viral or tumor antigens. GPI-0100 is currently undergoing Phase I clinical trials at the Memorial Sloan-Kettering Cancer Center in New York, N.Y., and the University of Alabama at Birmingham Comprehensive Cancer Center in Birmingham, Ala.

Galenica Pharmaceuticals Inc. is a closely held company engaged in the development of novel products for the prevention and active immunotherapy of cancer and infectious diseases, including bioterrorism. The company's proprietary vaccine formulations integrate its immune enhancers and carriers with antigens designed using proteomic tools for optimal performance. The company's lead product, GPI-0100, has been licensed to Pfizer Inc. for use in animal vaccines, and to Endocyte, Inc. Press releases and other corporate information can be found on Galenica's website at .
 For further information, please contact:
 Galenica Pharmaceuticals:
 David Vigor
 Executive Vice President
 (205) 982-8676

Make Your Opinion Count - Click Here

CONTACT: David Vigor, Executive Vice President of Galenica Pharmaceuticals, +1-205-982-8676, or

Web site:
COPYRIGHT 2002 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2002 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Geographic Code:1USA
Date:Oct 21, 2002
Previous Article:Lay Lake to be Lowered Beginning October 31, Reports Alabama Power.
Next Article:Medline Teams With Dial to Provide Quality Skin Care Products for Health Professionals; Co-Labeled Protection Plus(R) Soaps Targeted to Health...

Related Articles
Galenica Pharmaceuticals Awarded Patent for Chemically Modified Immune Enhancing Agents.
Galenica awarded patent for chemically modified immune enhancing agents.
Galenica Pharmaceuticals Presents Business Plan to Investors At SEBIO Conference.
Study Shows New Data Supporting ZADAXIN's Ability to Increase Th1 Subset Of T-Helper Cells; Data Presented at World Congress of Gastroenterology.
University of Alabama at Birmingham Comprehensive Cancer Center Initiate Phase I Trial of Novel HER-2 Vaccine for Breast Cancer; Trial will study...
Coley Pharmaceutical Group Identifies New Class of CpG Oligonucleotides; -- "C Class" CpG oligo shows potential to treat chronic viral infections --.
Galenica Pharmaceuticals Announces Collaboration With the National Center of Biotechnology in Madrid Spain To Develop A Safe Smallpox Subunit Vaccine.
Galenica acquisition finalized.
AustCancer's Galenica signs materials transfer agreement with Memorial Sloan-Kettering.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters